Navigation Links
Statins May Lower Rates of Prostate Cancer Recurrence

By Randy Dotinga
HealthDay Reporter

MONDAY, June 28 (HealthDay News) -- A new study suggests that men who take the cholesterol-lowering drugs known as statins are a third less likely to suffer from recurrences of prostate cancer.

But don't demand that your doctor prescribe a statin -- drugs such as Crestor, Lipitor and Zocor -- for you just yet.

The findings aren't firm enough for doctors to make a blanket recommendation about statin therapy for men who have had prostate cancer, said study senior author Dr. Stephen Freedland, an associate professor of urology and pathology at Duke University.

Another physician went further, saying the findings simply aren't convincing.

Some prior research has suggested that men who took the cholesterol-lowering drugs were less likely than other men to develop advanced prostate cancer and have it come back. But other studies haven't found such positive effects, so the jury is still out, said Dr. Nelson Neal Stone, a professor of urology and radiation oncology at Mount Sinai School of Medicine.

The goal of the new study was to see if statins might be helping those who had already had the disease.

The researchers examined the medical records of more than 1,300 men who'd had their prostates removed after being diagnosed with prostate cancer. Of those, 18 percent were taking a statin when they had the procedures.

The study results appear in the June 28 online issue of the journal Cancer.

After adjusting their statistics so they wouldn't be thrown off by factors such as high or low numbers or who were, say, obese or older, researchers found that those on statins were 30 percent less likely to suffer a recurrence of prostate cancer. More specifically, tumors recurred in 25 percent of those who didn't use statins and 16 percent of those who did.

The study doesn't prove a cause-and-effect relationship: The statins did not necessarily directly lower the risk of prostate cancer recurrence, the experts note. To confirm whether a drug actually reduces risk, researchers rely on studies -- unlike this one -- that randomly assign patients to certain treatments.

Stone added that the study has statistical problems that make its results questionable.

Still, men did better if they took higher doses of statins, Freedland said, suggesting that the drugs may have an effect. They may work by reducing inflammation that spurs tumor growth, he theorized.

Statins are among the most widely prescribed drugs in America, but they do come with risks. Patients may develop liver problems and muscle damage, although the likelihood of that is low, Freeland said.

And the drugs aren't as inexpensive as, say, aspirin. Statins can cost $5 a day or more, depending on dose, although some are much cheaper.

However, not every prostate cancer patient may need to take them, Freedland said. Tests at the time of surgery can estimate a man's risk of prostate cancer recurrence, and statins would be most appropriate for those at highest risk, he explained.

For now, Freedland doesn't recommend that prostate cancer patients start taking statins to prevent recurrence. However, "if you're already on a statin, I'd keep you on that statin," he said. "If you have a clear-cut indication, the benefits outweigh the risks."

More information

For more about prostate cancer, try the U.S. National Library of Medicine.

SOURCES: Stephen Freedland, M.D., associate professor, urology and pathology, Duke University, Durham, N.C.; Nelson Neal Stone, M.D., professor, urology and radiation oncology, Mount Sinai School of Medicine, New York City; June 28, 2010, Cancer, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Statins associated with lower cancer recurrence following prostatectomy
2. MSU team studies connection between statins, tendon ruptures
3. Too Many Stroke Patients Go Without Statins
4. Some statins have unintended effects and warrant closer monitoring, study finds
5. Statins decrease risk of clot-related diseases
6. Statins Wont Lower Colon Cancer Risk
7. Do Statins Lower Male Sex Drive?
8. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
9. Statins may slow progression of multiple sclerosis, new study finds
10. Alternative to Statins Shows Promise
11. Statins May Benefit Prostate Cancer Patients
Post Your Comments:
Related Image:
Statins May Lower Rates of Prostate Cancer Recurrence
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at ... Michigan, have come together on Thanksgiving Day to share the things that they ... on the Serenity Point YouTube channel, patients displayed what they wrote on index ...
(Date:11/26/2015)... NE (PRWEB) , ... November 26, 2015 , ... Jobs ... searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group ... during the month of October 2015 among those searching for healthcare jobs through the ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... Omaha, Neb. (PRWEB) , ... November 25, 2015 ... ... nurse staffing companies, has been recognized once again for its stellar workplace culture ... Places to Work.” , Medical Solutions’ Cincinnati office was named a ...
(Date:11/25/2015)... ... 25, 2015 , ... For the first time, Vitalalert is donating half of ... campaign. The partnership between the two groups began in 2014 with Vitalalert pledging a ... MAP International was founded in 1954 and is an international Christian-based health organization whose ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY USA ... continues to provide evidence demonstrating the accuracy of its ... Congress on Insulin Resistance, Diabetes and Cardiovascular Disease in ... both the Company,s GLUCOCARD ® 01 meter and ... accuracy requirements. The ability to accurately measure glucose levels ...
Breaking Medicine Technology: